Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Operations: 2011-2025

Historic Cash from Operations for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to -$19.3 million.

  • Enanta Pharmaceuticals' Cash from Operations rose 37.61% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.3 million, marking a year-over-year increase of 75.53%. This contributed to the annual value of -$19.3 million for FY2025, which is 75.53% up from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Cash from Operations stood at -$19.3 million for FY2025, which was up 75.53% from -$78.8 million recorded in FY2024.
  • Enanta Pharmaceuticals' Cash from Operations' 5-year high stood at -$19.3 million during FY2025, with a 5-year trough of -$103.2 million in FY2023.
  • Its 3-year average for Cash from Operations is -$67.1 million, with a median of -$78.8 million in 2024.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Cash from Operations slumped by 1,087.53% in 2021, and later surged by 75.53% in 2025.
  • Enanta Pharmaceuticals' Cash from Operations (Yearly) stood at -$70.0 million in 2021, then decreased by 21.12% to -$84.8 million in 2022, then declined by 21.67% to -$103.2 million in 2023, then increased by 23.64% to -$78.8 million in 2024, then skyrocketed by 75.53% to -$19.3 million in 2025.